Dans une bonne dynamique - ACHAT - OC 42€
La société annonçait hier après Bourse deux avis positifs du comité d’experts indépendants (DSMB) pour deux études : la phase I dans la LAL (leucémie lymphoblastique) en première ligne aux US et la phase II dans le cancer du pancréas en Europe. Ces bonnes nouvelles confirment ainsi notre thèse d’investissement qui intègre (i) une probabilité de succès de 50% dans la LAL, inspirée du succès de la phase III de Graspa® dans la LAL en Europe, ainsi que des premières ventes en 2019 et (ii) le cancer du pancréas, en phase précoce, qui reste selon nous une option libre à notre modèle de valorisation. Par conséquent, nous maintenons notre recommandation à ACHAT avec un objectif de cours de 42€/action.Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.